Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06838949 | A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP | PHASE2 | RECRUITING | 80 | — | — | Mar 3, 2025 | Dec 1, 2027 | Mar 13, 2025 | 1 | China |
Proportion of subjects with a platelet count ≥ 30 × 10\^9/L and at least twice the baseline platelet count without bleeding at week 8
| Arm | Type | Description |
|---|---|---|
| Herombopag | EXPERIMENTAL | Herombopag 2.5mg per tablet |
| Name | Type | Description |
|---|---|---|
| herombopag olamine tablets | DRUG | The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week. |
Inclusion Criteria: * Patients voluntarily participated in the study and signed informed consent; * Age ≥60 years old, gender unlimited; * ECOG PS ≤2; * Expected survival ≥6 months; * A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistent ITP; * PLT \< 30×109/L for at lea...